冷生长抑素类似物给药对生长抑素受体显像的影响:一项系统综述
该系统综述纳入12篇文章(4篇使用111In-喷曲肽,8篇使用68Ga-DOTA肽),评估冷生长抑素类似物(cSA)给药对SPECT或PET生长抑素受体(SSTR)显像中肿瘤及周围健康器官摄取的影响。结果显示cSA给药后脾脏和肝脏摄取持续降低(脾脏从6.9%至80%,肝脏从10%至60%),肿瘤/本底或肿瘤/健康器官比值升高,而肿瘤摄取本身不变或中度降低。结论认为cSA给药后SSTR显像质量受损未被证实,cSA给药似乎改善肿瘤病灶与周围组织的对比。
要点
- cSA给药后脾脏摄取降低6.9%至80%,肝脏摄取降低10%至60%。
- cSA给药后肿瘤/本底或肿瘤/健康器官比值升高,肿瘤摄取本身不变或中度降低。
- cSA给药后SSTR显像质量受损未被证实,cSA似乎改善肿瘤与周围组织的对比。
核心结论
- cSA给药后SSTR显像质量受损未被证实,cSA给药似乎改善肿瘤病灶与周围组织的对比。
研究设计与样本
- 系统综述,研究注册于Prospero(CRD42022360260),检索PubMed和Scopus数据库。
- 纳入标准:因肿瘤目的转诊行SSTR显像的人类患者;至少1次检查在cSA给药前或足够长的cSA洗脱后完成;至少1次检查在cSA治疗期间完成。
- 共纳入12篇文章,其中4篇使用111In-喷曲肽,8篇使用68Ga-DOTA肽。
- 由2名作者独立使用QUADAS标准化方案评价纳入文章,分歧通过共识解决。
主要发现
- cSA给药持续导致脾脏和肝脏摄取降低(脾脏从6.9%至80%,肝脏从10%至60%)。
- cSA给药后肿瘤/本底或肿瘤/健康器官比值升高。
- cSA治疗后肿瘤摄取本身不变或中度降低。
- 无论患者是否为奥曲肽初治,结果相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The interactions between the administration of cold somatostatin analogs (cSAs) and their radiolabeled counterpart remain unclear, and discontinuation before imaging is still advised as a precaution. The aim of this systematic review is to evaluate the consequences of cSA administration on tumoral and surrounding healthy organs' uptake at somatostatin receptor (SSTR) imaging with SPECT or PET. METHODS: After registration of the study on Prospero (CRD42022360260), an electronic search of PubMed and Scopus databases was performed. Inclusion criteria were as follows: human patients referred for SSTR imaging for oncological purposes; at least 1 examination performed either before cSA administration or after a long-enough withdrawal of cSA treatment; at least 1 examination was performed under cSA treatment. Included articles were independently appraised by 2 authors using the standardized protocol provided by the Quality Assessment of Diagnostic Accuracy Studies. Discrepancies were solved by consensus. RESULTS: A total of 12 articles were included, 4 using 111In-pentetreotide and 8 using 68Ga-DOTA peptides. Administration of cSAs consistently resulted in decreased spleen and liver uptake (from 6.9% to 80% for spleen, 10% to 60% for liver) and increased tumor-to-background or tumor-to-healthy organ ratios. After cSA treatment, tumor uptake alone was unchanged or moderately decreased. Similar results were noted whether patient was octreotide-naive. CONCLUSION: Impairment in SSTR imaging quality after cSA administration has not been demonstrated. On the contrary, the administration of cSAs seems to improve the contrast between tumoral lesions and the surroundings.
引用
- Morland D, Laures N, Triumbari EKA, et al. Impact of Cold Somatostatin Analog Administration on Somatostatin Receptor Imaging: A Systematic Review. Clin Nucl Med. 2023. PMID: 37133509. doi:10.1097/RLU.0000000000004670
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。